In the pharmaceutical sector, it's a mixed bag with some winners and some losers. The most eye-catching is MRK hitting a new high—the big brother is steady as ever!
MRNA also took the opportunity to surge a bit, showing that the vaccine sector still has some vitality.
Johnson & Johnson, on the other hand, seems to be lagging. Despite being favored by institutions, it's still falling. Those holding positions can relate to the frustration of "the logic isn't broken, but it just won't rise."
VOR's recent drop has been brutal—small-cap biotech stocks are indeed not for the faint-hearted.
Then there's GHRS, with its dramatic surge driven by news. If you didn't catch it, just sit back and watch. This year's U.S. pharma stocks have been full of drama, leaving people somewhat numb.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
